Showing results (41-50 of 80) with videos related to
Sort By:
Pageof 8
Annals of Nuclear Medicine|September 11, 2012
Significant impact of transient deterioration of renal function on dosimetry in PRRTSofie Van Binnebeek, Kristof Baete, Christelle Terwinghe, et al.Therapeutic Advances in Medical Oncology|August 21, 2023
A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in BelgiumLise Verbruggen, Lisa Verheggen, Greetje Vanhoutte, et al.Gut|June 3, 2019
<i>Kras</i> and <i>Lkb1</i> mutations synergistically induce intraductal papillary mucinous neoplasm derived from pancreatic duct cellsLouis Collet, Elsa Ghurburrun, Nora Meyers, et al.Journal of Neuroendocrinology|November 28, 2024
Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data 2010-2019Marlies Maly, Eduard Callebout, Suzane Ribeiro, et al.British Journal of Cancer|November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined responseAngela Lamarca, Jorge Barriuso, Matthew Kulke, et al.Acta Clinica Belgica|October 5, 2021
Quality of pathology reporting and adherence to guidelines in rectal neuroendocrine neoplasms: a Belgian national studyBruno Waked, Filip De Maeyer, Saskia Carton, et al.Journal of the National Cancer Institute|January 29, 2017
Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine CarcinomasAngela Lamarca, Thomas Walter, Marianne Pavel, et al.JAMA|May 4, 2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical TrialPascal Hammel, Florence Huguet, Jean-Luc van Laethem, et al.European Journal of Cancer (Oxford, England : 1990)|April 26, 2022
The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasmsIvan Borbath, Rocio Garcia-Carbonero, Damir Bikmukhametov, et al.Hepatic Oncology|September 8, 2018
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trialLorenza Rimassa, Camillo Porta, Ivan Borbath, et al.Pageof 8